genomic instability | human disease I nhibition of DNA repair has been proposed as a strategy for combating cancer (1) . Synthetic lethality is an approach that exploits preexisting DNA repair deficiencies in certain tumors to develop inhibitors of DNA repair pathways that compensate for the tumor-associated repair deficiency. Because helicases play critical roles in the DNA damage response and DNA repair, particularly in actively dividing and replicating cells, characterization of synthetic lethal relationships of DNA helicases may be of value in developing improved anticancer treatment strategies (2); moreover, small molecules that specifically target a given DNA helicase may be useful for understanding the role of the helicase in cellular nucleic acid metabolism.
We sought to identify and characterize a small-molecule inhibitor of a human RecQ helicase that is important for the cellular response to replicational stress. The RecQ family of DNA helicases has been implicated in the maintenance of genomic stability and human disease. Mutations in the Werner syndrome (WRN), Bloom's syndrome (BLM), and RecQ protein-like 4 (RECQL4) genes are responsible for the human disorders Werner syndrome, Bloom's syndrome, and Rothmund-Thomson syndrome, respectively (3) . RecQ helicases are required for normal cellular DNA replication, repair, and recombination. Although this interesting class of enzymes has been studied extensively, the precise functions of these proteins in vivo still are not well understood.
We chose to focus on the WRN helicase as a target for smallmolecule inhibition based on the plethora of evidence that WRN plays an important role in cell proliferation and DNA repair (4) (5) (6) . Werner syndrome is a premature aging disorder that displays many clinical symptoms of aging at an accelerated rate (7) . The WRN gene product that is defective in the chromosomal instability disorder has DNA helicase and exonuclease activities and interacts with a number of nuclear proteins to maintain genomic stability (8) . We investigated the hypothesis that a potent and specific WRN helicase inhibitor could be identified and used to inhibit WRN-dependent functions in vivo. Our findings provide evidence that a small molecule can modulate in vivo the function of a human helicase in the DNA damage response.
Results
In Vitro WRN Helicase Activity Screen of National Cancer Institute Diversity Set Compounds. The National Cancer Institute (NCI) Diversity Set library was screened for inhibitors of WRN helicase activity using an in vitro radiometric assay with a 19-bp forked duplex DNA substrate. Initially, a single 50-μM concentration of the compound was tested (Fig. S1A ). Approximately 70% of the DNA substrate was unwound by WRN incubated with 5% DMSO in the control reaction (Fig. S1A ). Compound 5 strongly inhibited WRN helicase activity. WRN helicase data from a larger group of 500 compounds from the NCI Diversity Set are shown in Fig. S1B . Seven of the small molecules identified from the initial screen were chosen for further analysis based on their ability to inhibit WRN helicase activity by 75% or more (Table S1 ). IC 50 values were determined from compound titrations as shown by NSC 19630 (Fig. S1 C and D) , giving a range of 2-20 μM for the small molecules tested (Fig. S1E) . To examine the specificity of WRN helicase inhibition, we tested the selected compounds on DNA unwinding catalyzed by two related human RecQ helicases (RECQ1 and BLM), Fanconi anemia group J (FANCJ) helicase mutated in Fanconi anemia, and three Escherichia coli helicases (RecQ, UvrD, and DnaB) (Table S2 ). Based on results from DNA unwinding assays with WRN and other helicases, two compounds (NSC 19630 and NSC 2805) inhibited WRN helicase activity but not the other six DNA helicases assayed.
Cell Proliferation Assays to Screen WRN Helicase Inhibitors. To determine if the small molecules identified by the in vitro WRN helicase activity screen were biologically active, we examined their effect on the proliferation of the human cervical cancer cell line HeLa 1.2 11 (hereafter abbreviated "HeLa"). HeLa cells were exposed to DMSO (as a control) or to increasing concentrations of selected small molecules for 0-3 d. Proliferation of compoundtreated cells was compared with the DMSO-treated cells. Of the compounds tested, NSC 19630 showed the greatest inhibition of cell proliferation at the lower concentrations (Fig. 1A) . NSC 19630 (3 μM) inhibited proliferation by 95% after day 2 (Fig. 1A) (Fig. S3) . WRN-depleted HeLa cells were treated with DMSO or 3 μM NSC 19630 for 0-3 d (Fig.  1B) . WRN-depleted HeLa cells grown in the presence of 3 μM NSC 19630 were resistant to its antiproliferative effects, whereas control siRNA HeLa cells were highly sensitive to NSC 19630 (Fig. 1B ). The other compounds tested (NSC 83224, NSC 42352, and NSC 2805) showed less significant inhibition of cell proliferation, and the antiproliferative effect was not dependent on WRN status, because WRN-depleted cells' sensitivity to the compound tested was similar to that of control cells (Fig. S3) . To assess if recovery of WRN expression after siRNA-mediated suppression reestablished NSC 19630 sensitivity, the WRN-depleted HeLa cells were allowed to continue to grow until WRN expression (through siRNA dilution by cell division) returned to a normal level (Fig. S4A) . At this stage, cells were treated with 3 μM NSC 19630 and were found to be sensitive to the compound as measured by cell proliferation (Fig. S4B) .
Because NSC 19630 exerted a WRN-dependent effect on cell proliferation, we evaluated whether BLM status affected cellular sensitivity to the compound. The results demonstrate that BLMnull and BLM-corrected cells display similar sensitivity to NSC 19630 (Fig. S4C) , indicating that BLM does not play a role in the antiproliferative effects of NSC 19630.
Effect of NSC 19630 on the Growth of NCI 60 Cancer Cell Lines. To evaluate further the biological effect of NSC 19630, existing data from the NCI Developmental Therapeutics Program were mined. This database contains information on the effects of small molecules from the NCI Diversity Set on growth of 60 human tumor cell lines from different cancer types. The most notable effect of NSC 19630 on cell growth was observed for leukemia cell lines, in which all six lines tested were inhibited by NSC 19630 (Fig. S5) . Growth also was suppressed by exposure to NSC 19630 in the majority of renal cancer cell lines and in certain human cell lines from other forms of cancer (colon, ovarian, and breast). Western blot analysis of WRN in cell lysates from the NCI collection suggests that, although there are differences in WRN protein levels, these differences do not correlate with the sensitivity of the cell lines to NSC 19630 (Fig. S5) .
Because some of the cancer cell lines were sensitive to NSC 19630, we examined the effect of the compound on noncancerous breast epithelial cells (MCF10A) and telomeraseimmortalized normal fibroblasts (NHF1-hTERT), both of which were found to be resistant to the antiproliferative effects of NSC 19630 as measured by the WST-1 proliferation assay (Fig. S6) (Fig. S7A) . At a concentration of NSC 19630 in which significant WRN helicase inhibition was observed, no binding to the forked duplex DNA molecules by the compound was detected. Because helicase activity is coupled to ATP hydrolysis, we examined the effect of NSC 19630 on WRN ATPase activity. NSC 19630 concentrations up to 50 μM had only a modest effect (19% reduction) on the k cat for ATP hydrolysis by WRN (Fig. S7B) . In contrast, WRN helicase activity was reduced by 75% at an NSC 19630 concentration of 50 μM. These results suggest that WRN helicase activity (IC 50 ∼20 μM) was more sensitive than WRN ATPase activity to inhibition by NSC 19630. We also observed that WRN exonuclease activity was reduced only mildly in the presence of 25 μM NSC 19630 (Fig. S7C) .
NSC 19630 Inhibits Cell Survival, Induces Apoptosis, and Causes Double-Strand Breaks. To evaluate the ability of the WRN helicase inhibitor NSC 19630 to affect cell growth, colony-formation assays were performed. HeLa cells were incubated with the small molecule or with DMSO for 3 d, subsequently allowed to grow in medium free of DMSO or NSC 19630 for 7 d, and then stained with methylene blue. A significant reduction in both the size and number of colonies was observed in cells exposed to NSC 19630 compared with control DMSO-treated cells (Fig. 1 C and D) . Quantitative analysis demonstrated a 55% reduction in colony number as a consequence of exposure to 2 μM NSC 19630 ( Fig. 1  C and D) . At 3 μM NSC 19630, an 85% reduction in colonies was observed ( Fig. 1 C and D) , indicating that the effect on cell growth was dependent on NSC 19630 concentration.
To test the effect of NSC 19630 on cellular mitogenic efficiency, we evaluated 5-ethynyl-2′-deoxyuridine (EdU) incorporation as a measure of DNA synthesis. HeLa cells exposed to NSC 19630 were impaired in their ability to synthesize DNA compared with control (DMSO) cells (Fig. 1 E and F) .
The negative effect of NSC 19630 exposure on cellular proliferation suggested that the compound also might affect apoptotic potential. HeLa cells exposed to 3 μM NSC 19630 displayed a fivefold increase in apoptosis compared with DMSOtreated cells (Fig. 2A) . There was no difference in the level of apoptosis in WRN siRNA HeLa cells treated with NSC 19630 and those treated with DMSO ( Fig. 2A) , suggesting that NSC 19630 induction of apoptosis is WRN dependent.
RecQ helicases are proposed to maintain and stabilize replication forks in response to endogenous stress or exogenous DNA damage (3, 9) . Failure to stabilize forks can lead to fork collapse and double-strand breaks (DSB). Therefore, we analyzed formation of γ-H2AX foci in NSC 19630-treated or control cells. Exposure of HeLa cells to 2 μM NSC 19630 elevated γ-H2AX foci ∼17-fold compared with DMSO-treated cells ( However, WRN is required for normal replication fork progression after DNA damage or replication fork arrest (6) . Because NSC 19630 exposure resulted in DSB accumulation, inhibition of DNA synthesis, and elevated apoptosis, we reasoned that cells treated with NSC 19630 might be delayed in their progression through S phase. To determine the effect of NSC 19630 on cell-cycle progression, WRN siRNA or control siRNA HeLa cells were exposed to 2 μM compound for 72 h and analyzed by flow cytometry. HeLa cells exposed to NSC 19630 displayed a significant increase in S-phase population (42% compared with 24% in DMSO-treated control cells) (Fig. S8B) . Mock-depleted cells exposed to NSC 19630 also displayed a significant increase in S-phase population similar to that observed with HeLa. However, no significant difference in S-phase population was seen in NSC 19630-versus DMSO-treated WRNdepleted cells, suggesting that NSC 19630 induces S-phase delay in a WRN-dependent manner. WRN depletion in HeLa cells did not affect the length of the S phase (Fig. S8C) , suggesting that inhibition of WRN helicase activity by NSC 19630 exerts a dominant negative effect on S-phase progression.
Proliferating Cell Nuclear Antigen Staining Revealed the Accumulation of Blocked Replication Forks in NSC 19630-Exposed Cells. Mammalian cells exposed to replication inhibitors or DNA damage that blocks replication fork progression display an enrichment of proliferating cell nuclear antigen (PCNA) foci that correspond to stalled replication forks and/or assembly sites of DNA repair proteins (10, 11) . Because cells exposed to the WRN helicase inhibitor NSC 19630 display a delayed S phase and accumulation of γ-H2AX foci, we wanted to determine whether PCNA foci staining would be increased and, if so, whether this increase occurred in a WRN-dependent manner. HeLa cells exposed to 2 μM NSC 19630 showed a significantly increased (∼20-fold) number of PCNA-staining foci compared with DMSO-treated cells (Fig. 3 A and B) . Exposure of human cells to small molecules such as telomestatin (TMS) that specifically bind G4 structures in vitro induce the dissociation of shelterin proteins [e.g., protection of telomeres 1 (POT1) and TATA box binding protein-related factor 2 (TRF2)] or telomere-associated proteins [e.g., topoisomerase III (TOP3)] from their telomeric sites (12) (13) (14) . TMS is proposed to compete with such proteins for binding to G4 DNA or stabilizing a G4 structure that is not favorably bound by the telomere-interacting protein, leading to telomere uncapping in cells with alternative lengthening of telomere (12, 14) . TMS also can reduce proliferation of telomerase-positive tumor cells effectively by inhibiting telomerase (13, 15) .
Because WRN can unwind G4 DNA substrates in vitro (16, 17) , and evidence suggests that WRN helicase activity has a specialized role in unwinding alternate DNA structures that form in the G-rich strand of the telomere end (18), we sought to determine if NSC 19630 and TMS might act synergistically to inhibit cell proliferation. Limited concentrations of TMS (0.6 μM) and of NSC 19630 (1 μM) exerted only mild effects on cell proliferation (Fig. 4A) . However, cotreatment of U2OS cells with both NSC 19630 and TMS inhibited cell proliferation by 70%, demonstrating an apparent synergistic effect.
NSC 19630 Increases Cellular Sensitivity to Poly(ADP Ribose) Polymerase Inhibitor. It was reported previously that inhibitors of the single-stranded break DNA repair protein poly(ADP ribose) polymerase 1 (PARP1) are synthetic lethal in homologous recombination (HR)-deficient cells with mutations in the breast cancer susceptibility proteins, breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) (19, 20) . It is believed that when PARP1 is inhibited, single-stranded breaks persist, leading to the collapse of replication forks in dividing cells that ultimately result in potentially toxic DSB. In BRCA-deficient cells, the absence of HR, which normally provides an error-free pathway to deal with replication fork-associated lesions, results in cell killing by concentrations of PARP inhibitor that are not toxic to HRproficient cells.
Given the prominence of the HR pathway of DSB repair in dealing with replication-associated lesions that accumulate in rapidly proliferating cells, we hypothesized that WRN helicase, which is known to have a role in HR, represented a target to enhance the cellular sensitivity to a known PARP inhibitor, KU0058948. HeLa cells were exposed to sublethal concentrations of KU0058948 (1 nM), NSC 19630 (1 μM), or a combination of the two compounds and were evaluated for cell proliferation. Cotreatment of HeLa cells with both NSC 19630 and the PARP inhibitor resulted in an ≈60% reduction in cell proliferation, whereas neither compound alone had any detectable effect (Fig. 4B) , suggesting that the PARP inhibitor and NSC 19630 act synergistically to inhibit cell proliferation. (Fig. 4C) . However, treatment of cells with both NSC 19630 (1 μM) and TPT (0.1 μM) resulted in an ≈50% reduction in cell proliferation (Fig. 4C) .
Cellular exposure to 1 μM NSC 19630 did not induce γ-H2AX foci formation, whereas exposure to 0.1 μM TPT resulted in, on average, four to five γ-H2AX foci per cell (Fig. 4 D and E) . However, in the presence of both TPT and NSC 19630, a significant (40-fold) increase in the number of γ-H2AX foci per cell was observed (Fig. 4 D and E) . These results demonstrate an apparent synergistic effect of NSC 19630 and TPT on DSB accumulation.
Discussion
Because of the importance of WRN in the replicational stress response, we sought to identify and characterize a small molecule that would modulate its biological function. To accomplish this goal, we screened the NCI Diversity Set using an in vitro helicase assay. A compound designated NSC 19630 (IC 50 = 20 μM) appeared to be specific based on its reduced ability to affect DNA unwinding by two other human RecQ helicases (BLM and RECQ1) and four additional helicases (FANCJ, RecQ, UvrD, and DnaB). Mining the NCI60 cancer cell line database showed that NSC 19630 inhibited growth of cell lines from various cancers with a particularly strong representation from leukemia (five of six cell lines) and renal cancer (five of eight cell lines). However, additional cell lines from other cancer types (e.g., colon and breast) also were sensitive to the antiproliferative effect of NSC 19630. The NCI Diversity Set has been distributed widely and tested in many high-throughput screens. In a study published in 2005, Bykov et al. (21) reported that NSC 19630 and related maleimide analogs induced apoptosis in mutant p53 cell lines by restoring wild-type conformation and function to mutant p53. In the current study, NSC 19630 induced apoptosis in both wildtype and mutant p53 backgrounds, suggesting that the effect of the molecule on WRN helicase activity may have contributed to the effects observed in the p53-mutant cell lines reported previously. Because the NCI Diversity Set has been incorporated into chemical libraries used by the National Institutes of Health Roadmap initiative, a substantial screening database exists for member compounds, including NSC 19630, and is accessible online via PubChem (http://pubchem.ncbi.nlm.nih.gov/summary/ summary.cgi?cid=227681&loc=ec_rcs). Although some activity was noted in particular screens, it is not apparent that such activity bears any relationship to the activity reported here.
Because NSC 19630 exerts its antiproliferative effects in the absence of exogenous DNA damage, the compound may interfere with the action of WRN on cellular DNA replication or repair intermediates that arise from endogenous DNA damage that accumulates in rapidly dividing cells. The difference in NSC 19630 concentration required for activity in cell culture versus biochemical assay may reflect conditions in the cell that render WRN more accessible to the compound compared with conditions used for in vitro biochemical reactions. Conceivably, NSC 19630 inhibits S-phase progression by forming a helicase-inactive WRN complex with other proteins or key DNA replication intermediates. Accumulation of DNA damage and PCNA foci, as well as ATM activation, are consistent with a model in which WRN helicase inhibition derails normal cellular DNA replication. WRN is unique among the RecQ helicases because the protein has dual helicase and exonuclease activities; however, the relative importance of WRN helicase and exonuclease activities in vivo is not well understood. Cell-based assays suggest a role for the WRN exonuclease activity in aspects of DSB end joining (22) , but the enzyme is proposed to have pleiotropic functions. The WRN helicase inhibitor may provide a tool to investigate the relative contributions of WRN helicase and exonuclease activities in DNA repair or replication. Further exploration of the synergistic effects of NSC 19630 and related compounds with DNA-damaging therapies (e.g., chemotherapy drugs and radiation) are warranted to define the WRN-mediated pathway(s) important for proper DNA repair or replicational stress response. Indeed, the abilities of the WRN helicase inhibitor NSC 19630 to sensitize cells to a PARP inhibitor or to a potential telomere-directed cancer therapy represent advances in this area. For the PARP inhibitor, we hypothesize that accumulation of strand breaks leads to genomic instability and inhibition of cell proliferation because the compromised HR repair pathway is compromised when WRN helicase is inhibited. Synergistic interaction between NSC 19630 and TMS in telomerase-negative cells probably reflects the importance of WRN helicase activity in resolving G4 and other alternate structures such as the T-loop associated with telomeres or other G-rich sequence elements.
In cancer therapeutics there is heightened interest in strategies amplifying tumor-specific replicative lesions by inhibiting specific DNA repair pathways (23) . Our laboratory has taken a particular interest in directed cancer therapy through helicase-targeted synthetic lethality (24) . Tumor cells with DNA repair deficiencies, either BRCA or mismatch repair, might be particularly vulnerable to therapeutic strategies targeting WRN. Certainly there is clinical precedent for this approach in the case of PARP inhibitors (25) . The cancer-or tumor-specific delivery of a small-molecule WRN helicase inhibitor remains an ongoing area of investigation. Future studies probably will address the use of helicase-specific inhibitors to target tumors with an existing DNA repair deficiency that rely more heavily on a WRN-dependent pathway for coping with endogenous or exogenously induced DNA damage.
Materials and Methods
Helicase Assays. Compounds were obtained as 10-mM stocks dissolved in DMSO and were stored at −20°C. Initially, a single 50-μM concentration of compound was tested for effect on WRN helicase activity. Compounds were diluted in DMSO to a concentration of 1,000 μM. Two microliters of diluted stock were added to 20 μL of reaction mixture so that final compound concentration was 50 μM. WRN helicase reactions using a forked duplex (19 bp) DNA substrate (0.5 nM) were initiated by the addition of 1.2 nM WRN and incubation at 37°C for 15 min as described (26) . RECQ1 (27) and FANCJ (28) helicase reactions were performed as described. Reaction conditions for BLM, DnaB, and UvrD were the same as for FANCJ. Helicase reactions were quenched, and reaction products were resolved on native 12% polyacrylamide gels as described (26) .
Cell Proliferation Assays. The effect of compounds on HeLa cell proliferation was determined using the WST-1 assay (Roche). Compounds were diluted in DMSO so that 10 μL of diluted stock in a 1-mL aliquot of HeLa cells (50,000 cells/mL) yielded a desired concentration of compound at 1% DMSO. HeLa cell cultures containing the specified compound were plated onto a 96-well microtiter plate at 5,000 cells per well in duplicate. As a control, 5,000 cells per well were seeded in medium containing 1% DMSO in duplicate. For background subtraction, plates lacking cells but containing medium and compound were used. Plates were incubated at 37°C for 0-3 d, followed by addition of WST-1 reagent for 2 h. OD 450 was measured at indicated time intervals using a microplate reader (Bio-Rad). Similar assays were performed to determine the effect of selected compounds on proliferation of NHF1-hTERT, U2OS, BLM-null (PSNG13) or BLM-corrected (PSNF5), MCF10A, T47D, MCF7, and HeLa WRN siRNA and control-siRNA cells. Two microliters of the quenched reaction mixture were spotted on a 10 × 20 cm sheet of PEI Cellulose (JT Baker) 1 cm from the bottom edge with a 1.5-cm space between each spot. The cellulose sheet was placed vertically in a chamber containing TLC running buffer (1 M formic acid, 0.8 M LiCl) until the buffer front reached the top of the sheet. The sheet was removed, wrapped in plastic, and exposed for 30 min on a phosphorimager screen. The screen was scanned in a Typhoon scanner (GE), and spots were quantitated. A graph of product (ATP hydrolyzed) per unit time was generated, and the slope of the fitted line was divided by the amount of WRN (nmol) to generate k cat values for WRN ATP hydrolysis.
ACKNOWLEDGMENTS.
Exonuclease Assays. WRN was incubated with the indicated concentrations of NSC 19630 in a 10-μL reaction containing Exonuclease buffer [40 mM Tris (pH 8.0), 2 mM MgCl 2 , 5 mM DTT, 100 μg/mL BSA, 1 mM ATP, and 0.25 nM 5′ tail DNA substrate]. Reactions were initiated by the addition of WRN (15 nM) and incubated at 37°C for 20 min. Reactions were terminated by the addition of 10 μL formamide loading buffer followed by 3-min incubation at 95°C. Reaction products were resolved on denaturing 14% polyacrylamide gels and visualized using a PhosphorImager.
WRN Silencing in HeLa Cells. The sequence of WRN siRNA was 5′-GTGTATAGTTACGATGCTAGTGATT-3′, and that of the control siRNA was 5′-UUCUCCGACGUGUCACGUUU-3′. siRNA was transfected using Lipofectamine 2000 following the manufacturer's protocol (Invitrogen). Cells were plated to 50-60% confluence in 10-cm dishes 24 h before transfection. siRNA (0.6 nmol) was mixed with 30 μL of Lipofectamine 2000 in 3 mL of Opti-MEM (Invitrogen). The mixture was added to cells that subsequently were incubated for 6 h. After 24 h, a second transfection was performed similarly. Seventy-two hours after the initial transfection, cells were harvested for preparing lysate or were treated with small-molecule compounds or DMSO at the indicated concentrations, and cell proliferation was measured using WST-1 reagent (Roche) as described in Materials and Methods for HeLa cells.
For experiments with siRNA-transfected cells that were allowed to recover WRN expression, WRN-depleted HeLa cells were grown for 2 wk after 48 h of initial siRNA-WRN transfection. Cells were harvested for preparing lysate or were treated with small-molecule compounds or DMSO at the indicated concentrations, and cell proliferation was measured using WST-1 reagent.
For lysate preparation, cells were washed twice with 1× PBS. RIPA buffer [10 mM sodium phosphate (pH 7.2), 300 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 1% deoxycholate, 2 mM EDTA] was added to the cells, and the cells were incubated at 4°C for 30 min. Cells were scraped, and the suspension was incubated further on ice for 30 min. Then the cell suspension was centrifuged at 18,500 × g for 10 min at 4°C, and supernatant was collected. Twenty micrograms of the lysate were loaded on 8-16% SDS/PAGE. Protein was transferred onto a PVDF membrane, and the blot was probed with anti-WRN antibody (1:1,000) (Spring Valley Laboratories) as the primary antibody. For the secondary antibody, peroxidase-labeled anti-mouse IgG (1:1,000) (Vector) was used. The blot was developed using the ECL Plus Western Blot Detection Kit according to the manufacturer's protocol (Amersham). As a loading control, the blot was stripped and then reprobed with anti-actin antibody (1:5,000) (Sigma).
For analysis of the WRN expression levels in National Cancer Institute (NCI) 60 cancer lines, cell lysates for all the cell lines were prepared and analyzed for WRN protein by Western blot as described above. The percentage of WRN expressed in each cell line then was calculated relative to the amount of WRN expressed in HeLa as 100%. WRN protein levels in the NCI60 cell lines were analyzed relative to the pattern of NSC 19630 sensitivity using the COMPARE algorithm (6) via an interactive tool available at the NCI website (dtp.nci.nih.gov). The pattern of WRN protein expression was not significantly correlated with the pattern of cellular sensitivity to NSC 19630 (correlation coefficient = 0.17). solution. The sample was mixed by inversion and incubated at room temperature in the dark for at least 1 h before analysis. Samples then were analyzed on a FACScan (Becton Dickinson).
To determine the effect of WRN knockdown on the length of S phase, control siRNA or WRN siRNA-depleted HeLa cells were treated with 0.5 μM mimosine for 16 h. Cells then were washed with PBS and incubated with fresh medium for 8 h. At this time, mimosine-treated cells had reached mid to late S phase. Aliquots of cells were collected at the indicated time intervals and prepared for FACScan analysis as described above.
Detection of Ataxia Telangiectasia Mutated Phosphorylation upon NSC 19630 Cellular Exposure. HeLa cells were treated with either 1% DMSO or 2 μM NSC 19630 for the indicated time periods. Cells then were harvested by centrifugation at 1600 × g for 10 min at 4°C, washed once with PBS, and resuspended in RIPA buffer [10 mM sodium phosphate (pH 7.2), 300 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 1% deoxycholate, and 2 mM EDTA] containing protease and phosphatase inhibitor mixture and were incubated at 4°C for 30 min. Cells were incubated further on ice for 30 min and centrifuged at 18,500 × g for 10 min at 4°C. The supernatant was collected, and 200 μg of the lysate was loaded on 4% SDS/PAGE. Following electrophoresis, protein was transferred onto a PVDF membrane, and blot was probed with anti-pATM Ser1981 antibody (1:500) (Santa Cruz). For the secondary antibody, peroxidase-labeled anti-mouse IgG (1:1,000) (Vector) was used. The blot was developed using the ECL Plus Western Blot Detection Kit following the manufacturer's protocol (Amersham). As a control, the blot was stripped and then reprobed with anti-ataxia telangiectasia mutated (ATM) antibody (1:500) (Millipore).
Colony Survival Assays. To measure colony survival, 250 HeLa cells per well were seeded in a six-well plate 24 h before treatment. Cells then were exposed to the indicated concentrations of NSC 19630 or 1% DMSO as a control for 72 h at 37°C. Following exposure, cells were washed twice with 1× PBS and incubated in a regular maintenance medium (DMEM, 10% FBS) at 37°C for 7 d. Colonies formed were fixed in methanol, stained with methylene blue (Sigma), and counted to determine percentage survival relative to the DMSO control.
DNA Synthesis by EdU Incorporation. HeLa cells (25,000 cells per well) were treated with 2 μM NSC 19630 or with DMSO as a control for 72 h in four-well chamber slides (Lab-Tek). EdU (10 μM) (Invitrogen) was added to the culture medium, and slides were incubated at 37°C for 6 h. Cells were washed twice with 1× PBS and fixed with 3.7% formaldehyde at room temperature for 15 min. Following fixation, cells were washed twice with 3% BSA and treated with 0.5% Triton X-100 at room temperature for 20 min. After permeabilization, cells were washed twice with 3% BSA. Then 0.5 mL Click-iT reaction mixture (1× Click-iT reaction buffer, CuSO4, Alexa Fluor 594 azide, and reaction buffer additive) (Invitrogen) was added to each well and was incubated at room temperature in the dark for 30 min. Cells were washed once with 3% BSA and coated with Prolong Gold Anti-Fade reagent containing DAPI (Invitrogen). Coverslips were placed on chamber slides, and cells were cured at room temperature in the dark for 24 h. Immunofluorescence analyses were performed with a Zeiss LSM 510 META inverted Axiovert 200 M laser scan microscope with a Plan-Apochromat 100× 1.4-numericalaperature oil immersion differential interference contrast objective lens. Images were captured with a CCD camera and analyzed using the LSM Browser software package.
γ-H2AX Foci Detection by Immunofluorescence. HeLa cells were treated with 2 μM NSC 19630 or 1% DMSO as a control for 72 h in slide chambers with four wells (Lab-Tek). Cells then were washed twice with 1× PBS and fixed with formaldehyde (3.7%) at room temperature for 15 min. Fixed cells were washed four times with 1× PBS and treated with 0.5% Triton X-100 (Sigma) at room temperature for 5 min. Cells were washed four times with 1× PBS containing 0.5% Tween-20 and blocked with 10% goat serum (Sigma) overnight at 4°C. Cells were washed four times with 0.1% Tween-20 and incubated with mouse anti-γ-H2AX monoclonal antibody (1:300) (Upstate) or mouse proliferating cell nuclear antigen (PCNA) F-2 monoclonal antibody (1:500) (Santa Cruz) overnight at 4°C. After four washes with 0.1% Tween-20, cells were incubated with Alexa Fluor 488-conjugated donkey antimouse IgG (1:400) (Invitrogen) at room temperature for 2 h. Cells were washed four times with 0.1% Tween-20 and coated with Prolong Gold Anti-Fade reagent (Invitrogen) containing DAPI. Coverslips were placed on the chamber slides, and cells were cured at room temperature in the dark for 24 h. Immunofluorescence analyses were performed as described above.
To determine the effect on γ-H2AX foci formation of the combined exposure of HeLa cells to TPT and NSC 19630, cells were cotreated with the indicated compound concentrations at 37°C for 72 h. Cells were fixed with formaldehyde and processed for immunostaining to detect γ-H2AX foci as described above.
Cellular Apoptosis Assays. HeLa cells were exposed to the indicated concentrations of NSC 19630 or 1% DMSO as a control for 72 h at 37°C. To assay apoptosis, the cytoplasmic histone-associated DNA fragments indicative of ongoing apoptosis were measured quantitatively using the cell death detection ELISA PLUS photometric enzyme assay (Roche). 
